Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDFAST-study
2024-519774-40-00Phase 4Authorised
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of naltrexone + bupropion in obesity, Overweight, metabolic dysfunction-associated steatotic liver disease (MASLD) and 4 more (2 arms), sponsored by Franciscus Gasthuis & Vlietland. Planned start Apr 2025; status: authorised.
02
Drugs
naltrexone + bupropion
03
Conditions
obesityOverweightmetabolic dysfunction-associated steatotic liver disease (MASLD)hepatic fibrosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-519774-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519774-40-00.